Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorpheniramine + dextromethorphan
- Development stage
- Unknown
- Lead developer
- AMBIENS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Exocuf-DC is a combination pharmaceutical product developed and marketed by Ambiens Pharmaceuticals, primarily indicated for the symptomatic relief of dry cough. It is formulated as a sugar-free, raspberry-flavored syrup containing two active ingredients: chlorpheniramine maleate and dextromethorphan hydrobromide. Chlorpheniramine is a first-generation antihistamine that acts as a competitive antagonist at the histamine H1 receptor, reducing allergic symptoms such as sneezing and rhinorrhea. Dextromethorphan is a non-opioid antitussive that acts centrally on the cough center in the medulla oblongata, primarily through sigma-1 receptor agonism and NMDA receptor antagonism, to elevate the cough threshold. The product is typically used for coughs associated with the common cold, flu, or other respiratory tract infections.
- Brand names
- Exocuf-DC
- Other names
- Exocuf-DC SyrupExocuf-DC Syrup Raspberry Sugar FreeChlorpheniramine maleate + Dextromethorphan hydrobromide
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)SIGMAR1 (Sigma non-opioid intracellular receptor 1)KCNH2 (Voltage-gated potassium channel subfamily H member 2)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on chlorpheniramine + dextromethorphan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorpheniramine + dextromethorphan.